Dianthus Therapeutics Stock Net Income
| DNTH Stock | 52.33 0.43 0.82% |
As of the 26th of January, Dianthus Therapeutics shows the Mean Deviation of 2.73, downside deviation of 2.9, and Semi Deviation of 2.42. Dianthus Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Dianthus Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 598.562 | Revenue | Earnings Share (3.50) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -76.5 M | -80.3 M | |
| Net Loss | -76.5 M | -72.6 M | |
| Net Loss | -25.6 M | -26.9 M | |
| Net Loss | (2.30) | (2.41) |
Dianthus | Net Income | Build AI portfolio with Dianthus Stock |
Latest Dianthus Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Dianthus Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Dianthus Therapeutics financial statement analysis. It represents the amount of money remaining after all of Dianthus Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Dianthus Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dianthus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (84.97 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Dianthus Net Income Regression Statistics
| Arithmetic Mean | (37,056,329) | |
| Coefficient Of Variation | (81.46) | |
| Mean Deviation | 26,761,211 | |
| Median | (28,476,000) | |
| Standard Deviation | 30,187,377 | |
| Sample Variance | 911.3T | |
| Range | 75.5M | |
| R-Value | (0.76) | |
| Mean Square Error | 407.7T | |
| R-Squared | 0.58 | |
| Significance | 0.0004 | |
| Slope | (4,554,847) | |
| Total Sum of Squares | 14580.4T |
Dianthus Net Income History
Other Fundumenentals of Dianthus Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Dianthus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Dianthus Therapeutics is extremely important. It helps to project a fair market value of Dianthus Stock properly, considering its historical fundamentals such as Net Income. Since Dianthus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dianthus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dianthus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.50) | Revenue Per Share | Quarterly Revenue Growth (0.82) | Return On Assets | Return On Equity |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Dianthus Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Dianthus Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Dianthus Therapeutics.
| 10/28/2025 |
| 01/26/2026 |
If you would invest 0.00 in Dianthus Therapeutics on October 28, 2025 and sell it all today you would earn a total of 0.00 from holding Dianthus Therapeutics or generate 0.0% return on investment in Dianthus Therapeutics over 90 days. Dianthus Therapeutics is related to or competes with Enliven Therapeutics, Taysha Gene, Sana Biotechnology, ATAI Life, Nektar Therapeutics, AnaptysBio, and Oculis Holding. Dianthus Therapeutics is entity of United States More
Dianthus Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Dianthus Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Dianthus Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.9 | |||
| Information Ratio | 0.1401 | |||
| Maximum Drawdown | 22.1 | |||
| Value At Risk | (4.51) | |||
| Potential Upside | 8.0 |
Dianthus Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dianthus Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Dianthus Therapeutics' standard deviation. In reality, there are many statistical measures that can use Dianthus Therapeutics historical prices to predict the future Dianthus Therapeutics' volatility.| Risk Adjusted Performance | 0.1249 | |||
| Jensen Alpha | 0.6749 | |||
| Total Risk Alpha | 0.2579 | |||
| Sortino Ratio | 0.1961 | |||
| Treynor Ratio | (1.12) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Dianthus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Dianthus Therapeutics January 26, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1249 | |||
| Market Risk Adjusted Performance | (1.11) | |||
| Mean Deviation | 2.73 | |||
| Semi Deviation | 2.42 | |||
| Downside Deviation | 2.9 | |||
| Coefficient Of Variation | 627.18 | |||
| Standard Deviation | 4.05 | |||
| Variance | 16.43 | |||
| Information Ratio | 0.1401 | |||
| Jensen Alpha | 0.6749 | |||
| Total Risk Alpha | 0.2579 | |||
| Sortino Ratio | 0.1961 | |||
| Treynor Ratio | (1.12) | |||
| Maximum Drawdown | 22.1 | |||
| Value At Risk | (4.51) | |||
| Potential Upside | 8.0 | |||
| Downside Variance | 8.39 | |||
| Semi Variance | 5.86 | |||
| Expected Short fall | (3.39) | |||
| Skewness | 1.35 | |||
| Kurtosis | 3.7 |
Dianthus Therapeutics Backtested Returns
Dianthus Therapeutics appears to be not too volatile, given 3 months investment horizon. Dianthus Therapeutics secures Sharpe Ratio (or Efficiency) of 0.2, which denotes the company had a 0.2 % return per unit of standard deviation over the last 3 months. By reviewing Dianthus Therapeutics' technical indicators, you can evaluate if the expected return of 0.81% is justified by implied risk. Please utilize Dianthus Therapeutics' Mean Deviation of 2.73, downside deviation of 2.9, and Semi Deviation of 2.42 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Dianthus Therapeutics holds a performance score of 15. The firm shows a Beta (market volatility) of -0.57, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Dianthus Therapeutics are expected to decrease at a much lower rate. During the bear market, Dianthus Therapeutics is likely to outperform the market. Please check Dianthus Therapeutics' coefficient of variation, semi variance, price action indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Dianthus Therapeutics' price patterns will revert.
Auto-correlation | 0.37 |
Below average predictability
Dianthus Therapeutics has below average predictability. Overlapping area represents the amount of predictability between Dianthus Therapeutics time series from 28th of October 2025 to 12th of December 2025 and 12th of December 2025 to 26th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Dianthus Therapeutics price movement. The serial correlation of 0.37 indicates that just about 37.0% of current Dianthus Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.37 | |
| Spearman Rank Test | 0.38 | |
| Residual Average | 0.0 | |
| Price Variance | 18.09 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Dianthus Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Dianthus Therapeutics reported net income of (84.97 Million). This is 124.9% lower than that of the Biotechnology sector and 221.31% lower than that of the Health Care industry. The net income for all United States stocks is 114.88% higher than that of the company.
Dianthus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dianthus Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dianthus Therapeutics could also be used in its relative valuation, which is a method of valuing Dianthus Therapeutics by comparing valuation metrics of similar companies.Dianthus Therapeutics is currently under evaluation in net income category among its peers.
Dianthus Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Dianthus Therapeutics from analyzing Dianthus Therapeutics' financial statements. These drivers represent accounts that assess Dianthus Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Dianthus Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 344.3M | 243.4M | 23.7M | 53.6M | 61.6M | 58.6M | |
| Enterprise Value | 286.2M | 111.8M | 9.1M | (78.1M) | (89.9M) | (85.4M) |
Dianthus Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Dianthus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Dianthus Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Dianthus Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (101.74) % | ||||
| Current Valuation | 1.84 B | ||||
| Shares Outstanding | 42.88 M | ||||
| Shares Owned By Insiders | 3.30 % | ||||
| Shares Owned By Institutions | 96.70 % | ||||
| Number Of Shares Shorted | 6.14 M | ||||
| Price To Book | 4.11 X | ||||
| Price To Sales | 728.95 X | ||||
| Revenue | 6.24 M | ||||
| Gross Profit | 3.08 M | ||||
| EBITDA | (101.45 M) | ||||
| Net Income | (84.97 M) | ||||
| Total Debt | 1.49 M | ||||
| Book Value Per Share | 12.75 X | ||||
| Cash Flow From Operations | (78.18 M) | ||||
| Short Ratio | 9.48 X | ||||
| Earnings Per Share | (3.50) X | ||||
| Target Price | 65.09 | ||||
| Number Of Employees | 78 | ||||
| Beta | 1.26 | ||||
| Market Capitalization | 2.24 B | ||||
| Total Asset | 374.01 M | ||||
| Retained Earnings | (174.39 M) | ||||
| Working Capital | 262.45 M | ||||
| Net Asset | 374.01 M |
About Dianthus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dianthus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dianthus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dianthus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:Check out Dianthus Therapeutics Piotroski F Score and Dianthus Therapeutics Altman Z Score analysis. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.50) | Revenue Per Share | Quarterly Revenue Growth (0.82) | Return On Assets | Return On Equity |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.